Phase 3 clinical trials are primarily conducted to evaluate which of the following?

• A. Efficacy and monitoring of adverse effects
• B. Safety and efficacy
• C. Manufacturing feasibility
• D. Marketing potential

Answer: (A)

Phase 3 trials are about confirming that the drug works in a larger, more diverse patient population while systematically collecting data on adverse effects to establish the safety profile. This large-scale efficacy testing, paired with monitoring for adverse effects, gives a solid understanding of the risk-benefit balance before potential approval. Manufacturing feasibility is addressed earlier in development and isn’t the primary goal of Phase 3, and marketing potential is not evaluated by the trial data itself. Safety and efficacy is true in spirit, but Phase 3 emphasizes the thorough monitoring of adverse effects to define safety in a broader population.